The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.
Results from ARISE II are promising for J&J/Cerenovus's EmboTrap stent-retriever for treatment of acute ischemic stroke, according to data presented at the International Stroke Conference.
Cerenovus is a J&J brand launched in October to include the products the company gained from its acquisition of